TargEDys and Inoliva announce they have entered a distribution partnership to bring Satylia(R) to Turkey
PR97997
LONGJUMEAU, France, Sept. 27, 2022, /PRNewswire=KYODO JBN/--
TargEDys and Inoliva, an affiliate of Abdi Ibrahim, have signed an exclusive
marketing and distribution agreement to bring Satylia, a food supplement based
on the next-generation probiotic Hafnia alvei HA4597, to the Turkish market.
Satylia, also called EnteroSatys in other markets, is a precision probiotic
with a characterized mechanism of action at molecular level: it increases
feelings of fullness thanks to the probiotic's protein ClpB that mimics the
satiety hormone alpha-MSH. Its efficacy was demonstrated in a clinical trial
involving 230 overweight adults. It is a new, natural, safe, and effective
solution to weight management and a multi-award winner.
Turkey has a population of 85 million and is the highest-ranking country in
Europe for obesity and overweight.
Grégory Lambert, CEO of TargEDys:
"We are thrilled about this new collaboration. Inoliva, with its premium and
scientific positioning, backed by the superb pharmaceutical establishment of
Abdi Ibrahim, is the best possible partner for Satylia!"
Aslı Biçer, General Manager of Inoliva:
"The weight management category has a volume growth of 76% in Turkey, due to a
growing number of people with obesity and increasing awareness on healthy
living. We wanted to exist in this market with a clinically-proven, natural,
side-effect-free and sustainable solution. Satylia is exactly what we were
looking for. Our goal is to improve the eating habits of consumers and become
#1 choice among weight management brands."
About Inoliva and Abdi Ibrahim
Inoliva is a pioneering pharmaceutical company formed under the leadership of
experienced specialists, driven by the mission to provide the public with
access to revolutionary products that aid in the preservation of life.
The strategy of Inoliva is multi-channel with a focus on dieticians, a strong
relationship with the pharmacist's network, combined with a DTC promotion.
Abdi Ibrahim, the leading pharmaceutical company in Turkey, acquired 90% of
Inoliva's shares in 2021 and will focus on growth in consumer healthcare and
biotechnology in future years.
About TargEDys(R)
TargEDys(R) is a commercial-stage French biotech specialized in the development
of nutraceutical solutions through microbiome interventions. The company is
based on 15 years of research on the microbiota conducted within academic
laboratories. TargEDys(R) develops a product portfolio focusing on overweight,
undernutrition, and mental health, all based on the concept of PreciBiomic
strains backed by a molecular mechanism of action and in vivo studies.
www.targedys.com
CONTACT: Arnaud Faure & Nina Vinot ; bd@targedys.com
Logo - https://mma.prnewswire.com/media/1905616/TargEDys_Inoliva_Logo.jpg
SOURCE: TargEDys, Inoliva
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。